EMA Outlines Situations Warranting Postmarketing Studies

Drug Industry Daily
A A
Sponsors that use surrogate endpoints, such as biomarkers, in confirmatory cancer trials may need to provide postmarketing data to verify that the information used to gain marketing authorization in the EU remains valid in practice.

To View This Article:

Login

Subscribe To Drug Industry Daily